Centralized Pan-Middle East Survey on the Undertreatment of Hypercholesterolemia

Completed

• Conditions: Hypercholesterolemia

• Registration Number: NCT01604733
• Lead Sponsor: AstraZeneca

Brief Summary

Study objective is to evaluate the level of control of hypercholesterolemia in Egypt in patients taking lipid lowering agents for at least 3 months ( with no drug change or dose amendment for a minimum of 6 weeks).

Detailed Description

Centralized Pan-Middle East Survey on the Undertreatment of Hypercholesterolemia

Study Timeline

• Study Start: 2010-10
• Primary Completion: 2011-06
• Study Completion: 2011-06
• Status Verified: 2012-05
• Study First Submitted: 2012-05-21
• Study First Submitted QC: 2012-05-23
• Last Update Submitted: 2012-05-23
• Study First Posted: 2012-05-24
• Last Update Posted: 2012-05-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 1000

Inclusion Criteria

• 18 years and above on current lipid lowering drug for at least 3 months with no dose change for a minimum of 6 weeks
• Subject must provide informed consent and comply with the survey procedures

Exclusion Criteria

• Less than 18 years less than 3 months on antidyslipidemic agent Subjects who are unwilling or unable to provide informed consent

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The proportion of patients on lipid-lowering treatment reaching the LDL-C goals according to the NCEP ATP III/ updated 2004 NCEP ATP III , overall and by country	24 weeks

Secondary Outcome Measures

Name	Time	Method
The proportion of patients on lipid-lowering treatment reaching the LDL-C goals according to the NCEP ATP III/ updated 2004 NCEP ATP III , in the following sub-populations: - primary/secondary prevention patients and with metabolic syndromes	24 weeks
The proportion of patients on lipid-lowering treatment reaching the LDL-C goals according to the Third Joint European Task Force guideline, in the following sub-populations: - primary/secondary prevention patients and with metabolic syndromes	24 weeks
Determinants (e.g. patient and physician characteristics , country-specific guidelines or recommendations) for undertreatment of hypercholesterolemia	24 weeks
Physician characteristics associated with the allocation of treatment regimen.	24 weeks
The proportion of patients on lipid-lowering treatment reaching the non HDL-C goals according to the NCEP ATP III/ updated 2004 NCEP ATP III , in the sub-population patients with fasting triglycerides<200 mg/d	24 weeks